首页> 美国卫生研究院文献>American Journal of Cancer Research >Predictive values of serum VEGF and CRP levels combined with contrast enhanced MRI in hepatocellular carcinoma patients after TACE
【2h】

Predictive values of serum VEGF and CRP levels combined with contrast enhanced MRI in hepatocellular carcinoma patients after TACE

机译:TACE后肝细胞癌患者血清VEGF和CRP水平与MRI增强对比的预测价值

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study explored the predictive value of serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) levels combined with enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma (HCC) patients after transcatheter arterial chemoembolization (TACE). One hundred and seventeen patients who received TACE from June 2010 to December 2012 in our hospital were included in this study. Serum VEGF and CRP levels before and after TACE were determined by ELISA and single immunodiffusion method for analyzing the association of serum levels with pathological features. Enhanced MRI was utilized before and after TACE to measure tumor size and ADC value in enhanced region and non-enhanced region. MRI data were combined with serum VEGF and CRP levels to analyze the predictive value in efficacy and prognosis for HCC patients after TACE. The serum VEGF and CRP levels after TACE were increased, but can return to normal levels in a certain time. VEGF and CRP levels were not statistically associated with tumor location, tumor staining or presence of membrane (all P > 0.05), but closely correlated with combined portal vein tumor thrombus, combined arteriovenous fistula and distant metastasis (all P < 0.05). Low levels of serum VEGF and CRP, small tumor size and low ADC value before treatment indicated a better prognosis. The sensitivity and specificity of serum VEGF and CRP levels, tumor size and ADC value were respectively 92.31% and 88.46%, 93.85% and 90.38%, 81.54% and 78.85% as well as 47.69% and 84.62%. Serum VEGF and CRP levels, tumor size and ADC value could predict the efficacy of TACE for HCC patients. Serum VEGF and CRP levels combined with enhanced MRI may serve as markers for efficacy and prognosis evaluation in HCC patients after TACE.
机译:本研究探讨了经导管动脉化疗栓塞(TACE)后肝细胞癌(HCC)患者血清血管内皮生长因子(VEGF)和C反应蛋白(CRP)水平与增强磁共振成像(MRI)的预测价值。本研究纳入了2010年6月至2012年12月在我院接受TACE治疗的117例患者。通过ELISA和单一免疫扩散法测定TACE前后的血清VEGF和CRP水平,以分析血清水平与病理特征的关系。在TACE之前和之后使用增强MRI来测量增强区域和非增强区域的肿瘤大小和ADC值。 MRI数据与血清VEGF和CRP水平相结合,以分析TACE对HCC患者的疗效和预后的预测价值。 TACE后血清VEGF和CRP水平升高,但可在一定时间内恢复到正常水平。 VEGF和CRP水平与肿瘤的位置,肿瘤的染色或膜的存在无统计学相关性(所有P> 0.05),但与合并的门静脉肿瘤血栓,合并的动静脉瘘管和远处转移密切相关(所有P <0.05)。治疗前血清VEGF和CRP水平低,肿瘤小,ADC值低,预后较好。血清VEGF和CRP水平,肿瘤大小和ADC值的敏感性和特异性分别为92.31%和88.46%,93.85%和90.38%,81.54%和78.85%以及47.69%和84.62%。血清VEGF和CRP水平,肿瘤大小和ADC值可预测TACE对肝癌患者的疗效。血清VEGF和CRP水平与MRI增强相结合,可作为TACE后HCC患者疗效和预后评估的指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号